Centene Corporation(CNC)- NYSE
  • Fri, Sep. 9, 9:59 AM
    • Eli Lilly (NYSE:LLY) upgraded to Overweight from Neutral by JPMorgan. Price target raised to $95 (20% upside) from $92.
    • Ligand Pharmaceuticals (NASDAQ:LGND) upgraded to Hold from Sell by Deutsche Bank. Price target raised to $110 (2% downside risk) from $105.
    • Gilead Sciences (NASDAQ:GILD) upgraded to Buy from Hold by Jefferies. Price target raised to $91 (16% upside). Morgan Stanley rates it Hold with a price target of $100 (27% upside).
    • Teva Pharmaceutical Industries (NASDAQ:TEVA) upgraded to Outperform from Market Perform with a $66 price target by Oppenheimer.
    • Novo Nordisk (NYSE:NVO) downgraded to Neutral from Overweight by JPMorgan.
    • AbbVie (NYSE:ABBV) downgraded to Neutral from Overweight with a $73 (14% upside) price target by JPMorgan.
    • Cepheid (NASDAQ:CPHD) downgraded to Neutral from Buy by BTIG Research.
    • Tonix Pharmaceuticals (NASDAQ:TNXP) downgraded to Neutral from Buy by Roth Capital.
    • Momenta Pharmaceuticals (NASDAQ:MNTA) downgraded to Sell from Hold with a $6 (48% downside risk) price target by Maxim Group.
    • Biogen (NASDAQ:BIIB) downgraded to Hold from Buy with a $323 (7% upside) price target by Jefferies.
    • Centene (NYSE:CNC) downgraded to Market Perform from Outperform with an $80 (19% upside) price target by Leerink Swann. Wedbush rates it Outperform with an $85 (26% upside) price target.
    | Fri, Sep. 9, 9:59 AM | 12 Comments
  • Mon, Aug. 29, 1:38 AM
    • According to an analysis by the Kaiser Family Foundation, nearly a third of U.S. counties will likely be served by only one insurer that participates in an Affordable Care Act marketplace in 2017, representing an increase from 7% this year.
    • The data underscores the degree to which industry retrenchment from low enrollment and high service costs is curtailing options within the marketplaces.
    • Insurer departures will likely lead to higher prices, analysts have warned.
    • Related tickers: UNH, AET, ANTM, CI, HUM, WCG, CNC, MOH, GTS, HQY
    | Mon, Aug. 29, 1:38 AM | 16 Comments
  • Tue, Jul. 26, 7:10 AM
    • Centene (NYSE:CNC) Q2 Results ($M): Total Revenues: 10,897 (+97.9%); Premium and Service: 10,276 (+98.2%).
    • Net Income: 169 (+92.0%); EPS: 0.97 (+34.7%); Non-GAAP EPS: 1.29 (+69.7%); CF Ops (6 mo.): (225) (-157.0%).
    • Health Benefits Ratio: 86.6% (-2.1%).
    • Total Membership: 11,430,800 (+147.8%); Total At-Risk Membership: 8,615,100 (+94.2%).
    • 2016 Guidance: Total Revenues: $39.4B - 40.0B; EPS: $2.65 - 3.00; Non-GAAP EPS: $4.20 - 4.55; Health Benefits Ratio: 87.0 - 87.5%.
    • Shares are up 2% premarket on light volume.
    | Tue, Jul. 26, 7:10 AM | 1 Comment
  • Tue, Jul. 26, 6:02 AM
    • Centene (NYSE:CNC): Q2 EPS of $1.29 beats by $0.20.
    • Revenue of $10.9B (+97.8% Y/Y) beats by $110M.
    • Press Release
    | Tue, Jul. 26, 6:02 AM | 2 Comments
  • Mon, Jul. 25, 5:30 PM
  • Sun, Jul. 10, 9:47 AM
    • WellCare Health Plans (NYSE:WCG) and Centene (NYSE:CNC) have made competing offers for the Medicare Advantage insurance policies - covering about 350K people - that Aetna (NYSE:AET) plans to shed in order to acquire Humana (NYSE:HUM).
    • Aetna presented the divestiture plan on Friday, when meeting with DOJ officials in a bid to address their antitrust concerns.
    | Sun, Jul. 10, 9:47 AM | 2 Comments
  • Fri, Jul. 1, 10:28 AM
    • GlaxoSmithKline (NYSE:GSK) upgraded to Buy from Neutral by Citigroup. Price target is 1800p (14% upside).
    • Alexion Pharmaceuticals (NASDAQ:ALXN) upgraded to Buy from Neutral by Citigroup. Price target is $154 (29% upside).
    • IPG Photonics (NASDAQ:IPGP) upgraded to Buy from Hold by Canaccord Genuity. Price target raised to $90 (13% upside) from $85.
    • Centene (NYSE:CNC) upgraded to Overweight from Equal Weight by Morgan Stanley. Price target raised to $86 (21% upside) from $84.
    • Pacira Pharmaceuticals (NASDAQ:PCRX) downgraded to Hold from Buy by Brean Capital.
    • TESARO (NASDAQ:TSRO) downgraded to Hold from Buy by Jefferies.
    • Esperion Therapeutics (NASDAQ:ESPR) downgraded to Equal Weight from Overweight with a $13 (26% upside) price target (from $28) by Barclays. Downgraded to Neutral from Overweight with a $15 (46% upside) price target (from $50) by JPMorgan. Downgraded to Underperform from Neutral with a $10 (0% upside) price target (from $23) by Credit Suisse.
    • HeartWare International (NASDAQ:HTWR) downgraded to Market Perform from Outperform by Wells Fargo. Downgraded to Neutral from Buy with a $58 (0% upside) price target (from $60) by SunTrust Robinson Humphrey.
    • Regulus Therapeutics (NASDAQ:RGLS) downgraded to Market Perform from Outperform by BMO Capital. Price target lowered to $4 (30% upside) from $16.
    • HealthSouth (NYSE:HLS) downgraded to Underweight from Equal Weight by Barclays. Price target lowered to $42 (8% upside) from $45.
    • SciQuest (NASDAQ:SQI) downgraded to Market Perform from Outperform by Raymond James.
    • Quest Diagnostics (NYSE:DGX) downgraded to from Neutral to Sell by Jyske Bank.
    | Fri, Jul. 1, 10:28 AM | 5 Comments
  • Fri, Jun. 24, 7:01 AM
    • Cerner (NASDAQ:CERN) upgraded to Buy from Neutral with $65 (14% upside) price target by SunTrust Robinson.
    • Catalent (NYSE:CTLT) upgraded to Outperform from Market Perform with a $26 (midpoint)(10% upside) price target by Wells Fargo. Upgraded to Buy from Neutral by Bank of America.
    • Centene (NYSE:CNC) upgraded to Overweight from Equal Weight by Barclays. Price target raised to $82 (17% upside) from $76.
    • Valeant Pharmaceuticals (NYSE:VRX) downgraded to Neutral from Overweight by JPMorgan. Price target lowered to $35 (57% upside) from $50.
    • AveXis (NASDAQ:AVXS) downgraded to Hold from Buy by Jefferies. Price target lowered to $39 (3% downside risk) from $42.
    • Surgical Care Affiliates (NASDAQ:SCAI) downgraded to Neutral from Buy by JPMorgan. Price target maintained at $48 (3% upside).
    • ACADIA Pharmaceuticals (NASDAQ:ACAD) downgraded to Neutral from Buy by Bank of America.
    • Express Scripts Holdings (NASDAQ:ESRX) downgraded to Underweight from Equal Weight by Morgan Stanley. Price target raised to $70 (9% downside risk) from $67.
    • Perrigo (NYSE:PRGO) downgraded to Hold from Buy by Argus Research.
    • CVS Health (NYSE:CVS) downgraded to Equal Weight from Overweight by Morgan Stanley. Price target lowered to $104 (11% upside) from $111.
    | Fri, Jun. 24, 7:01 AM | 19 Comments
  • Tue, May 24, 9:38 AM
    • Worried about Fed rate hikes pushing the greenback up higher? Focus on growing companies deriving at least 80% of sales from the U.S., says Jefferies' Steven DeSanctis.
    • He notes the dollar peaked on Jan. 20, and sectors with big overseas exposure have outperformed since. However, with higher interest rates looking like they might send the dollar back into an uptrend, it's time to refocus on companies less reliant on exports.
    • DeSanctis and team identified 27 small- and mid-cap companies that were: In the Russell 2500 and Buy-rated by Jefferies, have less than 20% of sales outside of U.S., "sit in the highest two quintiles" based on ROE, and have market values north of $2B.
    • Of that group, they picked ten showing the highest growth of sales per share (though a tie brought the total to 11): Paycom Software (NYSE:PAYC), Lithia Motors (NYSE:LAD), Centene Corp. (NYSE:CNC), Molina Healthcare (NYSE:MOH), Five Below (NASDAQ:FIVE), Mednax (NYSE:MD), Western Alliance Bancorp (NYSE:WAL), Signature Bank (NASDAQ:SBNY), KAR Auction (NYSE:KAR), Science Applications (NYSE:SAIC), and Urban Outfitters (NASDAQ:URBN).
    | Tue, May 24, 9:38 AM | 6 Comments
  • Tue, Apr. 26, 6:59 AM
    • Centene (CNC) Q1 results: Revenues: $6,953M (+35.5%); SG&A: $722M (+82.3%); Operating Income: $20M (-84.5%); Net Loss: ($16M) (-125.0%); Loss Per Share: ($0.13) (-125.0%); Non-GAAP EPS: $0.74 (+34.5%); CF Ops: $195M (+333.3%); Quick Assets: $3,436M (95.2%).
    • 2016 Guidance: Total Revenues: $39.0B - 39.8B; EPS: $2.45 - 2.80; Non-GAAP EPS: $4.00 - 4.35.
    | Tue, Apr. 26, 6:59 AM
  • Tue, Apr. 26, 6:03 AM
    • Centene (NYSE:CNC): Q1 EPS of $0.74 beats by $0.01.
    • Revenue of $6.95B (+35.5% Y/Y) misses by $330M.
    • Press Release
    | Tue, Apr. 26, 6:03 AM
  • Mon, Apr. 25, 5:30 PM
    | Mon, Apr. 25, 5:30 PM | 15 Comments
  • Thu, Mar. 24, 5:43 PM
    • Abiomed (NASDAQ:ABMD) will take Hologic's spot in the S&P MidCap 400, and Ensco will take Centene's spot. First Industrial Realty Trust (NYSE:FR) will replace Health Net (just acquired by Centene) in the 400.
    • ServisFirst Bancshares (NASDAQ:SFBS) will replace National Penn Bancshares (about to be acquired by BB&T) in the S&P SmallCap 600 after the April 1 close. Banc of California (NYSE:BANC) will take Abiomed's spot in the 600.
    • HOLX +2% after hours. CNC +1.6%. FR +3.5%. BANC +3.5%. ESV -0.5%.
    | Thu, Mar. 24, 5:43 PM
  • Wed, Mar. 23, 12:40 PM
    • Health Net (HNT +4.7%) and Centene (CNC +5.6%) buck the market's down day. The bull catalyst is the approval of their planned merger by the California Department of Insurance. Centene announced its $6.8B takeover of Health Net in July 2015. The transaction should close shortly.
    • Previously: Centene takes out Health Net for $6.8B (July 2, 2015)
    | Wed, Mar. 23, 12:40 PM
  • Tue, Feb. 9, 7:42 AM
    • Centene (NYSE:CNC) Q4 results ($M): Total Revenues: 6,302 (+33.4%); Premiums: 5,415 (+34.8%); Total Operating Expenses: 6,082 (+34.2%).
    • Net Income: 111 (+3.7%); EPS: 0.90 (+2.3%); CF Ops: 658 (-46.2%).
    • Health Benefits Ratio: 88.0% (-1.5%); Total Membership: 5.1M (+25.8%).
    • 2016 Guidance: Total Revenues: $40.0B - 40.8B; EPS: $2.80 - 3.15; Non-GAAP EPS: $4.05 - 4.40.
    | Tue, Feb. 9, 7:42 AM
  • Tue, Feb. 9, 6:05 AM
    • Centene (NYSE:CNC): Q4 EPS of $0.95 beats by $0.09.
    • Revenue of $6.3B (+33.5% Y/Y) beats by $130M.
    | Tue, Feb. 9, 6:05 AM